NDLI: Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells.

Please wait, while we are loading the content...

Year: 2017 Volume: 103

Year: 2017 Volume: 102

Year: 2016 Volume: 101

Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects.

Development of immune-biomarkers of pulmonary tuberculosis in a rabbit model.

Antibodies and tuberculosis.

Highly sensitive sequence specific qPCR detection of Mycobacterium tuberculosis complex in respiratory specimens.

The impact of Bacille Calmette-Guérin shortage on immunisation practice and policies in Europe - A Paediatric Tuberculosis Network European Trials Group (ptbnet) survey.

BCG infection in mice is promoted by naïve mesenchymal stromal cells (MSC) and suppressed by poly(A:U)-conditioned MSC.

Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.

The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis.

The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.

Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.

MicroRNA expression signatures in lungs of mice infected with Mycobacterium tuberculosis.

Quick and cheap MIRU-VNTR typing of Mycobacterium tuberculosis species complex using duplex PCR.

Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis.

Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations.

Modulation of dendritic cell and monocyte subsets in tuberculosis-diabetes co-morbidity upon standard tuberculosis treatment.

Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: Involvement of TLR-4 mediated signaling.

Selective reduction of IFN-Î³ single positive mycobacteria-specific CD4+ T cells in HIV-1 infected individuals with latent tuberculosis infection.

Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis.

Innovative Tuberculosis Symposium held during Cuba Salud 2015.

Mycobacterium smegmatis proteoliposome induce protection in a murine progressive pulmonary tuberculosis model.

Transmission of multi-drug resistant tuberculosis in Mongolia is driven by Beijing strains of Mycobacterium tuberculosis resistant to all first-line drugs.

Primate models of tuberculosis. Faith-based or evidence-based science.

High body mass index is associated with heightened systemic and mycobacterial antigen - Specific pro-inflammatory cytokines in latent tuberculosis.

New Mycobacterium tuberculosis LAM sublineage with geographical specificity for the Old World revealed by phylogenetical and Bayesian analyses.

Relating annual migration from high tuberculosis burden country of origin to changes in foreign-born tuberculosis notification rates in low-medium incidence European countries.

Some proteins of M. tuberculosis that localise to the nucleus of THP-1-derived macrophages.

Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells.

Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.

Identification of SP110 in horse (Equus caballus): Isolation of novel splice variants and evidence of activation effects on macrophages.

An adverse immune-endocrine profile in patients with tuberculosis and type 2 diabetes.

Year: 2016 Volume: 100

Year: 2016 Volume: 99

Year: 2016 Volume: 98

Year: 2016 Volume: 97

Year: 2016 Volume: 96

Year: 2015 Volume: 95

Year: 2014 Volume: 94

Year: 2013 Volume: 93

Year: 2012 Volume: 92

Year: 2011 Volume: 91

Year: 2010 Volume: 90

Year: 2009 Volume: 89

Year: 2008 Volume: 88

Year: 2007 Volume: 87

Year: 2006 Volume: 86

Year: 2004 Volume: 84

Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Kayigire, Xavier A. Friedrich, Sven O. Karinja, Miriam N. Van Der Merwe, Lize Martinson, Neil A. Diacon, Andreas H.
Description	Author Affiliation: Kayigire XA ( Division of Molecular Biology and Human Genetics, MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa); Friedrich SO ( Division of Medical Physiology, MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa); Karinja MN ( Task Applied Science, Bellville, Cape Town, South Africa.); van der Merwe L ( Task Applied Science, Bellville, Cape Town, South Africa.); Martinson NA ( Perinatal HIV Research Unit, MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, University of the Witwatersrand, Johannesburg, South Africa.); Diacon AH ( Division of Medical Physiology, MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa)
Abstract	Propidium monoazide (PMA) penetrates non-viable cells with compromised membranes. PMA has been proposed to improve the specificity of Xpert MTB/RIF (Xpert) for the detection of viable Mycobacterium tuberculosis. This study assessed the effect of PMA on Xpert cycle thresholds (C ) of M. tuberculosis made non-viable under antibiotic pressure. In vitro, we measured the difference between C with and without PMA (ΔC ) in liquid cultures treated with one of six anti-tuberculosis drugs (isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin, moxifloxacin) and found significant ΔC only with isoniazid and ethambutol for pan-susceptible M. tuberculosis and only with ethambutol for extensively drug-resistant M. tuberculosis. In the clinic we assessed ΔC in sputum samples collected from patients with pulmonary tuberculosis before and at regular intervals over 12 weeks after initiation of treatment. Before treatment start, estimated C were 19.3 (95% CI: 17.1-21.4) and 19.8 (95% CI: 17.6-22.1) without and with PMA, respectively. Under treatment C increased by 2.54 per ââday (95% CI: 1.38-3.69) without PMA and an additional 0.55 per ââday (95% CI: 0.37-0.74; p < 0.0001) with PMA. We conclude that PMA increases the specificity of Xpert for viable M. tuberculosis but the effect is small and dependent on the antibiotics used.
File Format	HTM / HTML
ISSN	14729792
Journal	Tuberculosis
Volume Number	101
e-ISSN	1873281X
Language	English
Publisher	Elsevier
Publisher Date	2016-12-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pulmonary Medicine
Content Type	Text
Resource Type	Article
Subject	Infectious Diseases Immunology Microbiology Microbiology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in